Literature DB >> 7689612

Trypanosoma cruzi: immunity-induced in mice and rats by trypomastigote excretory-secretory antigens and identification of a peptide sequence containing a T cell epitope with protective activity.

A Taibi1, B Plumas-Marty, A Guevara-Espinoza, R Schöneck, H Pessoa, M Loyens, R Piras, T Aguirre, H Gras-Masse, M Bossus.   

Abstract

In the present study, we investigate the immunoprotective properties of trypomastigote excretory-secretory Ag (ESA) in experimental models. In the case of BALB/c mice, the immunization with ESA resulted in the reduction of parasitemia during acute infection and a significant level of protection in terms of mortality with more than 60% survival, whereas none of the mice in the control groups survived after 39 days postinfection. The same experiments performed in Fischer rats showed a high degree of protection against acute lethal infection with 100% survival, whereas 20 to 40% of rats in the control groups survived the acute phase of T. cruzi infection. Mouse and rat immune sera presented trypanolytic activity against Trypanosoma cruzi infective forms, and recognized two major parasite components of 85 and 24 kDa. The analysis of specific isotype profiles showed a predominance of IgG1, IgG2a, and IgG2b antibody responses. Rat antisera to ESA were then used to screen a trypomastigote cDNA library. Several clones were identified, all of which encoded for the 24-kDa protein. Using a mAb (Tcr7) produced against the native protein, the 31-kDa recombinant fusion protein was purified by affinity chromatography. The antisera to the recombinant protein used in IFA and immunoelectron microscopy showed that the localization of the 24-kDa protein differs among T. cruzi developmental stages. Protection experiments were performed in BALB/c mice using two synthetic peptides (20-40 and 109-124) derived from the primary sequence of the 24-kDa polypeptide. The results obtained clearly indicated that the peptide 109 to 124 containing a putative T cell epitope represents the most protective epitope, which induced 30 to 50% of protection against mortality during acute infection, whereas the percent survival in the control groups (OVA and 20-40 OVA peptide-immunized mice) was around 16%. Moreover, analysis of T cell proliferation in response to OVA-coupled peptides clearly indicated that only the 109 to 124 peptide had the capacity to induce the proliferation of T cells from peptide-immunized mice. Interestingly, only the 109 to 124-coupled peptide induced the proliferation of T cells from T. cruzi-infected mice.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7689612

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

1.  Vaccine-Linked Chemotherapy Improves Benznidazole Efficacy for Acute Chagas Disease.

Authors:  Kathryn Jones; Leroy Versteeg; Ashish Damania; Brian Keegan; April Kendricks; Jeroen Pollet; Julio Vladimir Cruz-Chan; Fabian Gusovsky; Peter J Hotez; Maria Elena Bottazzi
Journal:  Infect Immun       Date:  2018-03-22       Impact factor: 3.441

2.  Cysteine mutagenesis improves the production without abrogating antigenicity of a recombinant protein vaccine candidate for human chagas disease.

Authors:  Christopher A Seid; Kathryn M Jones; Jeroen Pollet; Brian Keegan; Elissa Hudspeth; Molly Hammond; Junfei Wei; C Patrick McAtee; Leroy Versteeg; Amanda Gutierrez; Zhuyun Liu; Bin Zhan; Jonathan L Respress; Ulrich Strych; Maria Elena Bottazzi; Peter J Hotez
Journal:  Hum Vaccin Immunother       Date:  2016-10-13       Impact factor: 3.452

Review 3.  Advances and challenges towards a vaccine against Chagas disease.

Authors:  Israel Quijano-Hernandez; Eric Dumonteil
Journal:  Hum Vaccin       Date:  2011-11-01

4.  A therapeutic nanoparticle vaccine against Trypanosoma cruzi in a BALB/c mouse model of Chagas disease.

Authors:  Meagan A Barry; Qian Wang; Kathryn M Jones; Michael J Heffernan; Munir H Buhaya; Coreen M Beaumier; Brian P Keegan; Bin Zhan; Eric Dumonteil; Maria Elena Bottazzi; Peter J Hotez
Journal:  Hum Vaccin Immunother       Date:  2016-02-18       Impact factor: 3.452

5.  Reactivity of chagasic antigal antibodies with noninfected cells treated with Trypanosoma cruzi secreted/excreted antigens.

Authors:  J K Yokoyama-Yasunaka; R M Piazza; E S Umezawa; A M Stolf
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

6.  Immunotherapy of Trypanosoma cruzi infection with DNA vaccines in mice.

Authors:  Eric Dumonteil; Javier Escobedo-Ortegon; Norma Reyes-Rodriguez; Arletty Arjona-Torres; Maria Jesus Ramirez-Sierra
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

7.  Pure paraflagellar rod protein protects mice against Trypanosoma cruzi infection.

Authors:  R A Wrightsman; M J Miller; J L Saborio; J E Manning
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

8.  Utility of recombinant flagellar calcium-binding protein for serodiagnosis of Trypanosoma cruzi infection.

Authors:  L M Godsel; R S Tibbetts; C L Olson; B M Chaudoir; D M Engman
Journal:  J Clin Microbiol       Date:  1995-08       Impact factor: 5.948

9.  Use of a 24-kilodalton Trypanosoma cruzi recombinant protein to monitor cure of human Chagas' disease.

Authors:  G M Krautz; L M Galvão; J R Cançado; A Guevara-Espinoza; A Ouaissi; A U Krettli
Journal:  J Clin Microbiol       Date:  1995-08       Impact factor: 5.948

10.  A 24,000 MW Trypanosoma cruzi antigen is a B-cell activator.

Authors:  A C Da Silva; A G Espinoza; A Taibi; A Ouaissi; P Minoprio
Journal:  Immunology       Date:  1998-06       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.